logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
21/06/2025
Bank of Wealth: downgrades Couchbase (BASE.US) rating from buy to hold, target price adjusted from $20.00 to $24.50.
Latest
3 m ago
Norway and Nord released the early results of the clinical trial for the hypoglycemic drug Amycretin. Amycretin showed signs of improving blood sugar levels. In the study, Amycretin demonstrated a weight loss effect of 24.3%.
3 m ago
Novo Nordisk releases early results of clinical trial for the blood sugar-lowering drug Amycretin. Amycretin shows signs of improving blood sugar levels. In the study, Amycretin has shown a weight reduction effect of 24.3%.
17 m ago
Futai Pharmaceutical (VRTX) presents positive data for Zimislecel (VX-880), a stem cell therapy for type 1 diabetes.
17 m ago
Futai Pharmaceuticals' stem cell therapy Zimislecel for type 1 diabetes shows positive data.
21 m ago
Securities Times front page: Let emotional consumption return to the appropriate "relaxation"
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.